Ardizzone, Sandro

Cassinotti, Andrea

Porro, Gabriele Bianchi

English

PubMed

A. Cassinotti

G. Bianchi Porro

S. Ardizzone

AIR Universita degli studi di Milano

Adalimumab for the treatment of Crohn's disease

A pilot study of adalimumab in inﬂ iximab-allergic patients. Inﬂ amm Bowel Dis,

Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial.

Adalimumab for maintenance treatment of Crohn’s disease:

Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. J Inherit Metab Dis. [Epub ahead of print] PMID:

Adalimumab in patients with Crohn’s disease – safety and efﬁ cacy in an open-label single centre study. Aliment Pharmacol Ther,

Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease.

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther,

Adalimumab induction therapy for Crohn’s disease previously treated with inﬂ iximab: a randomized trial. Ann Intern Med. Ann Intern Med,

Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to inﬂ iximab: an open-label study. Aliment Pharmacol Ther,

Adalimumab safety in Crohn’s disease and rheumatoid arthritis clinical trials, reduced mortality in rheumatoid arthritis [abstract].

Adalimumab-induced lupus erythematosus in Crohn’s disease patients previously treated with inﬂ iximab.

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn’s disease.

Adalimumab: a review of side effects. Expert Opin Drug Saf,

An open label study of adalimumab in Crohn’s disease patients with a loss of response to inﬂ iximab [abstract]. Gastroenterology, 130(Suppl 2):A–662(abstr W1225).

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to inﬂ iximab for Crohn’s disease.

Anti-TNF antibody induced stimulated T lymphocyte apoptosis depends on the concentration of the antibody and etanercept induces apoptosis at rates equivalent to inﬂ iximab and adalimumab at 10 micrograms per ml concentration. Gastroenterology,

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Autoimmune diseases induced by TNF-targeted therapies. Analysis of 233 cases.

Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease.

Binding and functional comparisons of two types of tumor necrosis factor antagonists.

Biologic therapy for inﬂ ammatory bowel disease.

Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric Gastroenmouse model. Inﬂ amm Bowel Dis,

Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem,

Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum,

Crohn’s disease: a review of current treatment with a focus on biologics.

Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study.

Efﬁ cacy and safety of short-term adalimumab treatment in patients with active Crohn’s disease who lost response or showed intolerance to inﬂ iximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther,

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol,

Eosinophilic cellulitis (Wells’ syndrome) as a cutaneous reaction to the administration of adalimumab. Ann Rheum Dis,

European Crohn’s and Colitis Organisation. European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. Gut, 55(Suppl 1):i16–i35.

Functional modulation of Crohn’s disease myoﬁ broblasts by anti-tumor necrosis factor antibodies.

Human anti-tumor necrosis factor monoclonal antibody (adalimumab)

Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol,

Immune responses following administration of inﬂ uenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.

Impact of screening for latent TB prior to initiating anti-TNF therapy

Incidence and importance of antibody response to inﬂ iximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol,

Inﬂ ammatory bowel disease: cause and immunobiology.

Inﬂ ammatory bowel disease: clinical aspects and established and evolving therapies.

Inﬂ iximab dose escalation vs initiation of adalimumab for loss of response in Crohn’s disease: a costeffectiveness analysis. Aliment Pharmacol Ther,

Inﬂ uence of immunogenicity on the long-term efﬁ cacy of inﬂ iximab in Crohn’s disease.

Inflammatory bowel disease: new insights into pathogenesis and treatment.

Intravenous hydrocortisone premedication reduces antibodies to inﬂ iximab in Crohn’s disease: a randomized controlled trial.

Localisation of tumor necrosis factor alpha by immunohistochemistry in chronic inﬂ ammatory bowel disease.

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inﬂ amm Bowel Dis,

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells. Comparison among inﬂ iximab, etanercept, and adalimumab. Arthritis Rheum,

Open label experience in adalimumab in pediatric Crohn’s disease patients who lost response or were intolerant to inﬂ iximab [abstract no.

Pharmacokinetic/ pharmacodynamic (PK/ PD) relationships of adalimumab (HUMIRA, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. Arthritis Rheum,

Pharmacokinetics of adalimumab from Classic, a randomized phase 3 trial for the induction of clinical remission in patients with Crohn’s [abstract].

Pharmacokinetics of adalimumab in a long-term investigation of the induction and maintenance of remission

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis,

Safety and efﬁ cacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to inﬂ iximab.

Severe anaphylactic reaction to inﬂ iximab: successful treatment with adalimumab – report of a case.

Skin reaction to adalimumab. Arthritis Rheum,

Successful use of adalimumab (Humira) for Crohn’s disease in pregnancy. Inﬂ amm Bowel Dis,

The successful use of adalimumab to treat active Crohn’s disease of an ileoanal pouch during pregnancy. Dig Dis Sci,

The use of adalimumab in the management of refractory Crohn’s disease. Aliment Pharmacol Ther,

Therapeutic monoclonal antibodies.

TNF alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol,

Treatment of Crohn’s disease by adalimumab anti-TNF monoclonal antibody in an inﬂ iximab-allergic patient [abstract no.

Treatment with adalimumab (D2E7) does not affect normal immune responsiveness. Arthritis Rheum,

Tumor necrosis factor alpha in stool as a marker of intestinal inﬂ ammation.

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Therap,

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity proﬁ les. Semin Arthritis Rheum,

Tumor necrosis factor: biology and therapeutic inhibitors.

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2727899

Adalimumab for the treatment of Crohn’s disease

Adalimumab for the treatment of Crohn’s disease

Abstract

Similar works

Full text

Available Versions

AIR Universita degli studi di Milano